20:59 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Bio-Path reports interim Phase II data for AML candidate

Bio-Path Holdings Inc. (NASDAQ:BPTH) reported interim data from 17 evaluable patients with previously untreated acute myelogenous leukemia (AML) who are ineligible for intensive induction therapy in a Phase II trial showing that prexigebersen (BP1001) plus...
17:35 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

BP1001: Ph II started

Bio-Path began an open-label, U.S. Phase II trial to evaluate 60 mg/m2 IV BP1001 given on day 1 and every 3 days thereafter plus low-dose cytarabine twice daily for 20 consecutive days in each 28-day...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Additional Phase I data

Data from 6 evaluable patients with advanced acute myelogenous leukemia (AML) in cohorts 7 and 8 of a dose-escalation Phase I trial showed that twice-weekly IV 60 or 90 mg/m 2 BP001 plus low-dose cytarabine...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Phase I data

Bio-Path disclosed in its 2Q15 earnings data from 21 evaluable patients from the monotherapy portion of a dose-escalation Phase I trial showing that IV liposomal Grb-2 was well tolerated with no DLTs reported. Additionally, liposomal...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2 regulatory update

FDA granted Orphan Drug designation to Liposomal Grb-2 from Bio-Path to treat acute myelogenous leukemia (AML). The liposomal antisense inhibitor of growth factor receptor-bound protein 2 (GRB2) expression is in Phase II testing for...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Phase II started

Bio-Path began an open-label, U.S. Phase II trial to evaluate 60 and 90 mg/m 2 IV BP-100-1.01 twice weekly in 28-day cycles in combination with cytarabine in 6 patients. Bio-Path Holdings Inc. (NASDAQ:BPTH), Houston, Texas...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Phase I amended

Bio-Path amended a dose-escalation Phase I trial evaluating IV BP-100-1.01 to include additional higher-dose cohorts due to the compound's "favorable safety profile." The trial, which has evaluated 5, 10, 20 and 40 mg/m 2 doses,...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Preliminary Phase I data

Preliminary data from 3 evaluable patients in the second cohort of a dose-escalation Phase I trial showed that twice-weekly 10 mg/m 2 IV BP-100-1.01 for 4 weeks was well tolerated with no treatment-related serious adverse...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Preliminary Phase I data

Preliminary data from 6 evaluable patients in the first cohort of a dose-escalation, U.S. Phase I trial showed that twice-weekly 5 mg/m 2 IV BP-100-1.01 for 4 weeks was well tolerated with no treatment-related serious...